The DolPHIN 2 team
Project Manager Helen leading a stakeholder mapping exercise
Visiting the Gugulethu site, Cape Town
Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.
The project will investigate whether dolutegravir is superior to efavirenz-based regimens (the current standard of care within sub-Saharan Africa) at preventing mother to child transmission of HIV for women who begin HIV treatment in the third trimester of pregnancy. We aim to establish high-quality evidence and operational guidance for the use of dolutegravir (DTG) in late pregnancy through:
- A multi-site clinical trial – taking place in Uganda and South Africa
- Qualitative studies – assessing the acceptability of dolutegravir and the reasons for late presentation in pregnancy
- A Pharmacoeconomic study – assessing the cost effectiveness of dolutegravir against the standard of care in South Africa and Uganda.
DolPHIN 2 is funded by UNITAID.
20 May 11:56
09 May 23:05
07 May 08:47
07 May 08:46
To sign up to our newsletter, please enter your details below: